Bayesian Applications in Pharmaceutical Development

1st Edition

Mani Lakshminarayanan, Fanni Natanegara

Chapman and Hall/CRC
August 20, 2019 Forthcoming
Reference - 464 Pages
ISBN 9781138296763 - CAT# K35632
Series: Chapman & Hall/CRC Biostatistics Series

For Instructors Request Inspection Copy

was $129.95


SAVE ~$25.99

Add to Wish List
FREE Standard Shipping!


The cost for bringing new medicine from discovery to market has nearly doubled in the last decade and has now reached $2.6 billion. There is an urgent need to make drug development less time-consuming and less costly. Innovative trial designs/analyses such as the Bayesian approach are essential to meet this need. This book will be the first to provide comprehensive coverage of Bayesian applications across the span of drug development, from discovery, to clinical trial, to manufacturing with practical examples.

This book will have a wide appeal to statisticians, scientists, and physicians working in drug development who are motivated to accelerate and streamline the drug development process, as well as students who aspire to work in this field. The advantages of our book are as follows:

  • Provides motivating, worked, practical case examples with easy to grasp models, technical details, and computational codes to run the analyses
  • Balances practical examples with best practices on trial simulation and reporting, as well as regulatory perspectives
  • Chapters written by authors who are individual contributors in their respective topics

Dr. Mani Lakshminarayanan is currently working as Vice-President, Clinical and Database Studies at Complete Health Economics Outcomes and Research Solutions (CHEORS). He has over 30 years of experience in the pharmaceutical industry. He has volunteered his time to the American Statistical Association (ASA) in various positions and to the DIA Bayesian Scientific Working Group (BSWG). He has a PhD in Statistics from Southern Methodist University, Dallas, Texas and is an ASA Fellow.

Dr. Fanni Natanegara has over 15 years of pharmaceutical experience and is currently Principal Research Scientist and Group Leader for the Early Phase Neuroscience Statistics team at Eli Lilly and Company. She played a key role in the Advanced Analytics team to provide Bayesian education and statistical consultation at Eli Lilly. Dr. Natanegara is the chair of the cross industry-regulatory-academic DIA BSWG to ensure that Bayesian methods are appropriately utilized for design and analysis throughout the drug-development process.


We provide complimentary e-inspection copies of primary textbooks to instructors considering our books for course adoption.

Request an
e-inspection copy

Share this Title